ID   SK-BR-3
AC   CVCL_0033
SY   SK-Br-3; Sk-Br-3; SK BR 03; SKBR-3; SKBr-3; SK-BR3; SKBr3; SkBr3; SKBR3
DR   BTO; BTO:0002419
DR   CLO; CLO_0009034
DR   CLO; CLO_0037295
DR   EFO; EFO_0001236
DR   MCCL; MCC:0000424
DR   CLDB; cl4310
DR   CLDB; cl7143
DR   AddexBio; C0006007/65
DR   ArrayExpress; E-MTAB-2706
DR   ArrayExpress; E-MTAB-2770
DR   ArrayExpress; E-TABM-157
DR   ArrayExpress; E-TABM-244
DR   ATCC; HTB-30
DR   BCRJ; 0226
DR   BioSample; SAMN01821597
DR   BioSample; SAMN03471462
DR   BioSample; SAMN10987910
DR   CCLE; SKBR3_BREAST
DR   CCRID; 3111C0001CCC000085
DR   CCRID; 3131C0001000700049
DR   CCRID; 3142C0001000000313
DR   CCTCC; GDC0286
DR   Cell_Model_Passport; SIDM00897
DR   ChEMBL-Cells; CHEMBL3308062
DR   ChEMBL-Targets; CHEMBL613834
DR   CLS; 300333/p3803_SK-BR-3
DR   Cosmic; 687499
DR   Cosmic; 755294
DR   Cosmic; 759896
DR   Cosmic; 871159
DR   Cosmic; 894090
DR   Cosmic; 897742
DR   Cosmic; 904385
DR   Cosmic; 921974
DR   Cosmic; 923062
DR   Cosmic; 934531
DR   Cosmic; 944297
DR   Cosmic; 979713
DR   Cosmic; 991329
DR   Cosmic; 997935
DR   Cosmic; 1000127
DR   Cosmic; 1010922
DR   Cosmic; 1018478
DR   Cosmic; 1044209
DR   Cosmic; 1046958
DR   Cosmic; 1129655
DR   Cosmic; 1136357
DR   Cosmic; 1176645
DR   Cosmic; 1287914
DR   Cosmic; 1289405
DR   Cosmic; 1308997
DR   Cosmic; 1434957
DR   Cosmic; 1524342
DR   Cosmic; 1571789
DR   Cosmic; 1609462
DR   Cosmic; 2036669
DR   Cosmic; 2165013
DR   Cosmic; 2301535
DR   Cosmic; 2318379
DR   Cosmic; 2361351
DR   DepMap; ACH-000017
DR   DSMZ; ACC-736
DR   GEO; GSM69195
DR   GEO; GSM73742
DR   GEO; GSM115115
DR   GEO; GSM149978
DR   GEO; GSM149986
DR   GEO; GSM149994
DR   GEO; GSM152556
DR   GEO; GSM152557
DR   GEO; GSM152558
DR   GEO; GSM152559
DR   GEO; GSM154096
DR   GEO; GSM154097
DR   GEO; GSM154098
DR   GEO; GSM154099
DR   GEO; GSM154100
DR   GEO; GSM154101
DR   GEO; GSM154102
DR   GEO; GSM154104
DR   GEO; GSM154107
DR   GEO; GSM155215
DR   GEO; GSM170624
DR   GEO; GSM170625
DR   GEO; GSM170626
DR   GEO; GSM170627
DR   GEO; GSM170630
DR   GEO; GSM170631
DR   GEO; GSM170633
DR   GEO; GSM170634
DR   GEO; GSM183440
DR   GEO; GSM183441
DR   GEO; GSM186457
DR   GEO; GSM186458
DR   GEO; GSM217596
DR   GEO; GSM274644
DR   GEO; GSM274663
DR   GEO; GSM344357
DR   GEO; GSM344407
DR   GEO; GSM350501
DR   GEO; GSM378146
DR   GEO; GSM421883
DR   GEO; GSM481334
DR   GEO; GSM590106
DR   GEO; GSM595617
DR   GEO; GSM783927
DR   GEO; GSM827582
DR   GEO; GSM845399
DR   GEO; GSM847432
DR   GEO; GSM847499
DR   GEO; GSM844686
DR   GEO; GSM844687
DR   GEO; GSM887575
DR   GEO; GSM888658
DR   GEO; GSM1008913
DR   GEO; GSM1038850
DR   GEO; GSM1038851
DR   GEO; GSM1038852
DR   GEO; GSM1038853
DR   GEO; GSM1038854
DR   GEO; GSM1053720
DR   GEO; GSM1172989
DR   GEO; GSM1172895
DR   GEO; GSM1214572
DR   GEO; GSM1238124
DR   GEO; GSM1264069
DR   GEO; GSM1264074
DR   GEO; GSM1264111
DR   GEO; GSM1264116
DR   GEO; GSM1374872
DR   GEO; GSM1374873
DR   GEO; GSM1374874
DR   GEO; GSM1401659
DR   GEO; GSM1661988
DR   GEO; GSM1833627
DR   IARC_TP53; 580
DR   IBRC; C10147
DR   ICLC; HTL03005
DR   IPD-IMGT/HLA; 12368
DR   IZSLER; BS TCL 156
DR   KCB; KCB 200723YJ
DR   KCLB; 30030
DR   LiGeA; CCLE_391
DR   LINCS_HMS; 50057
DR   LINCS_LDP; LCL-1475
DR   Lonza; 70
DR   NCBI_Iran; C207
DR   PharmacoDB; SKBR3_1383_2019
DR   PRIDE; PXD000691
DR   PRIDE; PXD002053
DR   PRIDE; PXD002057
DR   PRIDE; PXD002281
DR   PRIDE; PXD002486
DR   PRIDE; PXD005390
DR   RCB; RCB2132
DR   TKG; TKG 0592
DR   TOKU-E; 3129
DR   Wikidata; Q7390592
RX   CelloPub=CLPUB00423;
RX   DOI=10.1007/978-1-4757-1647-4_5;
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=1013510;
RX   PubMed=3518877;
RX   PubMed=6500159;
RX   PubMed=6582512;
RX   PubMed=6935474;
RX   PubMed=7017212;
RX   PubMed=9671407;
RX   PubMed=10862037;
RX   PubMed=11044355;
RX   PubMed=12800145;
RX   PubMed=15677628;
RX   PubMed=16397213;
RX   PubMed=16541312;
RX   PubMed=17157791;
RX   PubMed=18516279;
RX   PubMed=19582160;
RX   PubMed=19593635;
RX   PubMed=19727395;
RX   PubMed=20070913;
RX   PubMed=20215515;
RX   PubMed=21247443;
RX   PubMed=21378333;
RX   PubMed=22460905;
RX   PubMed=22585861;
RX   PubMed=23151021;
RX   PubMed=23601657;
RX   PubMed=23671654;
RX   PubMed=24009699;
RX   PubMed=24094812;
RX   PubMed=24162158;
RX   PubMed=24176112;
RX   PubMed=25485619;
RX   PubMed=25960936;
RX   PubMed=26055192;
RX   PubMed=26378940;
RX   PubMed=28196595;
RX   PubMed=28287265;
RX   PubMed=28889351;
RX   PubMed=29954844;
RX   PubMed=30894373;
RX   PubMed=31068700;
WW   https://en.wikipedia.org/wiki/SKBR3
WW   http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/sk-br-3.htm
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=SK-BR-3
WW   http://www.proteinatlas.org/learn/cellines
WW   http://lincs.hms.harvard.edu/resources/reagents/icbp43/
WW   http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/s/cell-lines-detail-57.html
WW   https://www.mskcc.org/research-advantage/support/technology/tangible-material/human-breast-cell-line-sk-br-3
WW   https://www.synapse.org/#!Synapse:syn2346643/wiki/62255
WW   http://tcpaportal.org/mclp/
WW   http://www.cellresource.cn/fdetail.aspx?id=85
WW   http://www.cellresource.cn/fdetail.aspx?id=618
WW   http://www.cellresource.cn/fdetail.aspx?id=1964
CC   Part of: Cancer Cell Line Encyclopedia (CCLE) project.
CC   Part of: GrayJW breast cancer cell line panel.
CC   Part of: ICBP43 breast cancer cell line panel.
CC   Part of: KuDOS 95 cell line panel.
CC   Part of: MD Anderson Cell Lines Project.
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Registration: Memorial Sloan Kettering Cancer Center Office of Technology Development; SK 808.
CC   Doubling time: ~30 hours (CLS); ~2-3 days (DSMZ); 56.19 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   HLA typing: A*02:01,02:01; B*14:02,39/50/55; C*03:04,03:04; DQB1*06:04,02:02 (PubMed=25960936).
CC   HLA typing: DPB1*03:01; DRB1*13:02 (IPD-IMGT/HLA; 12368).
CC   Microsatellite instability: Stable (MSS) (PubMed=23671654).
CC   Sequence variation: Homozygous for CDH1 deletion (PubMed=19593635).
CC   Sequence variation: Homozygous for TP53 p.Arg175His (c.524G>A) (ClinVar=VCV000012374) (PubMed=16541312; PubMed=28889351; ATCC; CCLE).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep antibody staining analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep proteome analysis.
CC   Omics: Deep RNAseq analysis.
CC   Omics: Exosome proteome analysis.
CC   Omics: Genome sequenced.
CC   Omics: Glycoproteome analysis by proteomics.
CC   Omics: miRNA expression profiling.
CC   Omics: N-glycan profiling.
CC   Omics: Protein expression by reverse-phase protein arrays.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Genome ancestry: African=0.7%; Native American=0%; East Asian, North=2.13%; East Asian, South=0%; South Asian=0.26%; European, North=63.89%; European, South=33.02% (PubMed=30894373).
CC   Misspelling: SKBR3B; In PubMed=26378940.
CC   Discontinued: RCB; RCB2132; true.
CC   Discontinued: TKG; TKG 0592; true.
CC   Derived from metastatic site: Pleural effusion.
ST   Source(s): AddexBio; ATCC; CLS; DSMZ; KCLB; MSKCC; PubMed=25877200; PubMed=28889351; RCB
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 11,12
ST   D16S539: 9
ST   D18S51: 10,13
ST   D19S433: 14
ST   D21S11: 30,30.2
ST   D2S1338: 20,25
ST   D3S1358: 17
ST   D5S818: 9,12 (AddexBio; ATCC; CCRID; CLS; DSMZ; KCLB; PubMed=25877200; PubMed=28889351; RCB)
ST   D5S818: 9 (MSKCC)
ST   D7S820: 9,12
ST   D8S1179: 12 (CCRID; MSKCC; PubMed=25877200)
ST   D8S1179: 11,12 (CLS)
ST   FGA: 20
ST   Penta D: 9,12
ST   Penta E: 10,11
ST   TH01: 8,9
ST   TPOX: 8,11
ST   vWA: 17
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_1074 ! AU565
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-07-20; Version: 31
//
RX   CelloPub=CLPUB00423;
RA   Morrison B.J.;
RT   "Breast cancer stem cells: tumourspheres and implications for therapy.";
RL   Thesis PhD (2010), Griffith University, Australia.
//
RX   DOI=10.1007/978-1-4757-1647-4_5;
RA   Fogh J., Trempe G.L.;
RT   "New human tumor cell lines.";
RL   (In) Human tumor cells in vitro; Fogh J. (eds.); pp.115-159; Springer; New York (1975).
//
RX   DOI=10.1016/B978-0-12-333530-2.50009-5;
RA   Leibovitz A.;
RT   "Cell lines from human breast.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=1013510; DOI=10.1007/978-3-642-81043-5_5;
RA   Trempe G.L.;
RT   "Human breast cancer in culture.";
RL   Recent Results Cancer Res. 57:33-41(1976).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6500159; DOI=10.1159/000163283;
RA   Gershwin M.E., Lentz D., Owens R.B.;
RT   "Relationship between karyotype of tissue culture lines and
RT   tumorigenicity in nude mice.";
RL   Exp. Cell Biol. 52:361-370(1984).
//
RX   PubMed=6582512; DOI=10.1073/pnas.81.2.568;
RA   Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.;
RT   "Cell surface antigens of human ovarian and endometrial carcinoma
RT   defined by mouse monoclonal antibodies.";
RL   Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
//
RX   PubMed=6935474; DOI=10.1093/jnci/66.2.239;
RA   Wright W.C., Daniels W.P., Fogh J.;
RT   "Distinction of seventy-one cultured human tumor cell lines by
RT   polymorphic enzyme analysis.";
RL   J. Natl. Cancer Inst. 66:239-247(1981).
//
RX   PubMed=7017212; DOI=10.1093/jnci/66.6.1003;
RA   Pollack M.S., Heagney S.D., Livingston P.O., Fogh J.;
RT   "HLA-A, B, C and DR alloantigen expression on forty-six cultured human
RT   tumor cell lines.";
RL   J. Natl. Cancer Inst. 66:1003-1012(1981).
//
RX   PubMed=9671407; DOI=10.1038/sj.onc.1201814;
RA   Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.;
RT   "Lack of relationship between CDK activity and G1 cyclin expression in
RT   breast cancer cells.";
RL   Oncogene 16:2865-2878(1998).
//
RX   PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B;
RA   Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F.,
RA   Isola J., Larsson C.;
RT   "Chromosomal alterations in 15 breast cancer cell lines by comparative
RT   genomic hybridization and spectral karyotyping.";
RL   Genes Chromosomes Cancer 28:308-317(2000).
//
RX   PubMed=11044355; DOI=10.1054/bjoc.2000.1458;
RA   Davidson J.M., Gorringe K.L., Chin S.-F., Orsetti B., Besret C.,
RA   Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.;
RT   "Molecular cytogenetic analysis of breast cancer cell lines.";
RL   Br. J. Cancer 83:1309-1317(2000).
//
RX   PubMed=12800145; DOI=10.1002/gcc.10218;
RA   Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B.,
RA   Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A.,
RA   Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D.,
RA   Edwards P.A.W., Chaffanet M.;
RT   "A recurrent chromosome translocation breakpoint in breast and
RT   pancreatic cancer cell lines targets the neuregulin/NRG1 gene.";
RL   Genes Chromosomes Cancer 37:333-345(2003).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//
RX   PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853;
RA   Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M.,
RA   van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.;
RT   "BRCA1 mutation analysis of 41 human breast cancer cell lines reveals
RT   three new deleterious mutants.";
RL   Cancer Res. 66:41-45(2006).
//
RX   PubMed=16541312; DOI=10.1007/s10549-006-9186-z;
RA   Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.;
RT   "Thirteen new p53 gene mutants identified among 41 human breast cancer
RT   cell lines.";
RL   Breast Cancer Res. Treat. 99:97-101(2006).
//
RX   PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008;
RA   Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T.,
RA   Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T.,
RA   DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D.,
RA   Albertson D.G., Waldman F.M., McCormick F., Dickson R.B.,
RA   Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.;
RT   "A collection of breast cancer cell lines for the study of
RT   functionally distinct cancer subtypes.";
RL   Cancer Cell 10:515-527(2006).
//
RX   PubMed=18516279; DOI=10.1016/j.molonc.2007.02.004;
RA   Kenny P.A., Lee G.Y., Myers C.A., Neve R.M., Semeiks J.R.,
RA   Spellman P.T., Lorenz K., Lee E.H., Barcellos-Hoff M.H.,
RA   Petersen O.W., Gray J.W., Bissell M.J.;
RT   "The morphologies of breast cancer cell lines in three-dimensional
RT   assays correlate with their profiles of gene expression.";
RL   Mol. Oncol. 1:84-96(2007).
//
RX   PubMed=19582160; DOI=10.1371/journal.pone.0006146;
RA   Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J.,
RA   Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D.,
RA   Pollack J.R.;
RT   "Molecular profiling of breast cancer cell lines defines relevant
RT   tumor models and provides a resource for cancer gene discovery.";
RL   PLoS ONE 4:E6146-E6146(2009).
//
RX   PubMed=19593635; DOI=10.1007/s10549-009-0460-8;
RA   Hollestelle A., Nagel J.H.A., Smid M., Lam S., Elstrodt F.,
RA   Wasielewski M., Ng S.S., French P.J., Peeters J.K., Rozendaal M.J.,
RA   Riaz M., Koopman D.G., ten Hagen T.L.M., de Leeuw B.H.C.G.M.,
RA   Zwarthoff E.C., Teunisse A., van der Spek P.J., Klijn J.G.M.,
RA   Dinjens W.N.M., Ethier S.P., Clevers H., Jochemsen A.G., den Bakker M.A.,
RA   Foekens J.A., Martens J.W.M., Schutte M.;
RT   "Distinct gene mutation profiles among luminal-type and basal-type
RT   breast cancer cell lines.";
RL   Breast Cancer Res. Treat. 121:53-64(2010).
//
RX   PubMed=19727395; DOI=10.1371/journal.pone.0006888;
RA   Wadlow R.C., Wittner B.S., Finley S.A., Bergquist H., Upadhyay R.,
RA   Finn S., Loda M., Mahmood U., Ramaswamy S.;
RT   "Systems-level modeling of cancer-fibroblast interaction.";
RL   PLoS ONE 4:E6888-E6888(2009).
//
RX   PubMed=20070913; DOI=10.1186/1471-2407-10-15;
RA   Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M.,
RA   Yamamoto S., Oka M., Hirano T., Sasaki K.;
RT   "Breast cancer cell lines carry cell line-specific genomic alterations
RT   that are distinct from aberrations in breast cancer tissues:
RT   comparison of the CGH profiles between cancer cell lines and primary
RT   cancer tissues.";
RL   BMC Cancer 10:15-15(2010).
//
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
//
RX   PubMed=21247443; DOI=10.1186/gb-2011-12-1-r6;
RA   Edgren H., Murumagi A., Kangaspeska S., Nicorici D., Hongisto V.,
RA   Kleivi K., Rye I.H., Nyberg S., Wolf M., Borresen-Dale A.-L.,
RA   Kallioniemi O.;
RT   "Identification of fusion genes in breast cancer by paired-end
RT   RNA-sequencing.";
RL   Genome Biol. 12:R6.1-R6.13(2011).
//
RX   PubMed=21378333;
RA   Ford C.H.J., Al-Bader M., Al-Ayadhi B., Francis I.;
RT   "Reassessment of estrogen receptor expression in human breast cancer
RT   cell lines.";
RL   Anticancer Res. 31:521-527(2011).
//
RX   PubMed=22460905; DOI=10.1038/nature11003;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez F., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=23151021; DOI=10.1186/1471-2164-13-619;
RA   Grigoriadis A., Mackay A., Noel E., Wu P.J., Natrajan R., Frankum J.,
RA   Reis-Filho J.S., Tutt A.;
RT   "Molecular characterisation of cell line models for triple-negative
RT   breast cancers.";
RL   BMC Genomics 13:619-619(2012).
//
RX   PubMed=23601657; DOI=10.1186/bcr3415;
RA   Riaz M., van Jaarsveld M.T.M., Hollestelle A.,
RA   Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J.,
RA   Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A.C., Foekens J.A.,
RA   Martens J.W.M.;
RT   "miRNA expression profiling of 51 human breast cancer cell lines
RT   reveals subtype and driver mutation-specific miRNAs.";
RL   Breast Cancer Res. 15:R33-R33(2013).
//
RX   PubMed=23671654; DOI=10.1371/journal.pone.0063056;
RA   Lu Y., Soong T.D., Elemento O.;
RT   "A novel approach for characterizing microsatellite instability in
RT   cancer cells.";
RL   PLoS ONE 8:E63056-E63056(2013).
//
RX   PubMed=24009699; DOI=10.1371/journal.pone.0072704;
RA   Liu X., Nie H., Zhang Y.-B., Yao Y.-F., Maitikabili A., Qu Y.-P.,
RA   Shi S.-L., Chen C.-Y., Li Y.;
RT   "Cell surface-specific N-glycan profiling in breast cancer.";
RL   PLoS ONE 8:E72704-E72704(2013).
//
RX   PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020;
RA   Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A.,
RA   Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K.,
RA   McCormick F., Gray J.W.;
RT   "Glutamine sensitivity analysis identifies the xCT antiporter as a
RT   common triple-negative breast tumor therapeutic target.";
RL   Cancer Cell 24:450-465(2013).
//
RX   PubMed=24162158; DOI=10.1007/s10549-013-2743-3;
RA   Prat A., Karginova O., Parker J.S., Fan C., He X., Bixby L.,
RA   Harrell J.C., Roman E., Adamo B., Troester M., Perou C.M.;
RT   "Characterization of cell lines derived from breast cancers and normal
RT   mammary tissues for the study of the intrinsic molecular subtypes.";
RL   Breast Cancer Res. Treat. 142:237-255(2013).
//
RX   PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110;
RA   Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M.,
RA   Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S.,
RA   Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S.,
RA   Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J.,
RA   Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.;
RT   "Modeling precision treatment of breast cancer.";
RL   Genome Biol. 14:R110.1-R110.14(2013).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H.,
RA   Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y.,
RA   Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D.,
RA   Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D.,
RA   Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S.,
RA   Zhang Z.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25960936; DOI=10.4161/21624011.2014.954893;
RA   Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.;
RT   "A catalog of HLA type, HLA expression, and neo-epitope candidates in
RT   human cancer cell lines.";
RL   OncoImmunology 3:E954893-E954893(2014).
//
RX   PubMed=26055192; DOI=10.1021/acs.jproteome.5b00375;
RA   Cifani P., Kirik U., Waldemarson S., James P.;
RT   "Molecular portrait of breast-cancer-derived cell lines reveals poor
RT   similarity with tumors.";
RL   J. Proteome Res. 14:2819-2827(2015).
//
RX   PubMed=26378940; DOI=10.1021/acs.analchem.5b02586;
RA   Clark D.J., Fondrie W.E., Liao Z., Hanson P.I., Fulton A., Mao L.,
RA   Yang A.J.;
RT   "Redefining the breast cancer exosome proteome by tandem mass tag
RT   quantitative proteomics and multivariate cluster analysis.";
RL   Anal. Chem. 87:10462-10469(2015).
//
RX   PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005;
RA   Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P.,
RA   Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W.,
RA   Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D.,
RA   Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B.,
RA   Liang H.;
RT   "Characterization of human cancer cell lines by reverse-phase protein
RT   arrays.";
RL   Cancer Cell 31:225-239(2017).
//
RX   PubMed=28287265; DOI=10.1021/acs.jproteome.6b00470;
RA   Yen T.-Y., Bowen S., Yen R., Piryatinska A., Macher B.A., Timpe L.C.;
RT   "Glycoproteins in claudin-low breast cancer cell lines have a unique
RT   expression profile.";
RL   J. Proteome Res. 16:1391-1400(2017).
//
RX   PubMed=28889351; DOI=10.1007/s10549-017-4496-x;
RA   Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L.,
RA   Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E.,
RA   Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J.,
RA   Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E.,
RA   Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F.,
RA   Lakhani S.R.;
RT   "Multidimensional phenotyping of breast cancer cell lines to guide
RT   preclinical research.";
RL   Breast Cancer Res. Treat. 167:289-301(2018).
//
RX   PubMed=29954844; DOI=10.1101/gr.231100.117;
RA   Nattestad M., Goodwin S., Ng K., Baslan T., Sedlazeck F.,
RA   Rescheneder P., Garvin T., Fang H., Gurtowski J., Hutton E., Tseng E.,
RA   Chin C.-S., Beck T., Sundaravadanam Y., Kramer M., Antoniou E.,
RA   McPherson J.D., Hicks J., McCombie W.R., Schatz M.C.;
RT   "Complex rearrangements and oncogene amplifications revealed by
RT   long-read DNA and RNA sequencing of a breast cancer cell line.";
RL   Genome Res. 28:1126-1135(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747;
RA   Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//